Sign inJoin waitlistJoin the waitlist

Madhav Dhodapkar

Scientific Director, Multiple Myeloma Program, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Medical Oncology
Internal Medicine
SSM Health/Saint Louis University School of Medicine

Research

Antitumor activity of thalidomide in refractory multiple myeloma
New England Journal of Medicine · 1999 · 2,120 citations
Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
The Journal of Experimental Medicine · 2001 · First of 5 authors · Corresponding · 1,054 citations
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Journal of Clinical Oncology · 2016 · 869 citations

Kavita Dhodapkar
57 papers
Sagar Lonial
40 papers
Ajay Nooka
37 papers
BB
Bart Barlogie
33 papers
Jonathan Kaufman
32 papers
Craig Hofmeister
28 papers
Nisha Joseph
27 papers · 3 as a fellow
Sundar Jagannath
22 papers
Vikas Gupta
20 papers
Nikhil Munshi
12 papers
David Avigan
11 papers
David Vesole
11 papers

Grants

In Vivo Engineering of Virus-Specific T Cells for CAR T Cell Therapy Against Multiple Myeloma
National Cancer Institute · R01
PI · $705.9K · Georgia Institute of Technology
2026–2031
Improving Immune Modulation for Smoldering Myeloma
National Cancer Institute · R01
Contact PI · $1.4M · Fred Hutchinson Cancer Center
2024–2030
Adult Leukemia Research Center
National Cancer Institute · P01
Project lead · $850K · Fred Hutchinson Cancer Center
1997–2029
Targeting Microbial Triggers of Gammopathy for Immunoprevention
National Cancer Institute · UH3
Contact PI · $945.4K · Fred Hutchinson Cancer Center
2024–2029

Clinical trials

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2026–2028
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
Principal investigator · Recruiting · Phase 2
Fred Hutchinson Cancer Center
2026–2028
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Principal investigator · Terminated · Phase 1, Phase 2
Multiple Myeloma Research Consortium
2020–2024
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Principal investigator · Completed · Phase 2
Yale University
2011–2014